Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 18/20 | 0.48 |
| ▸ | ERBB2 | P04626 | 15/20 | 0.48 |
| ▸ | STK4 | Q13043 | 3/20 | 0.41 |
| ▸ | STK25 | O00506 | 1/20 | 0.41 |
| ▸ | CIT | O14578 | 1/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.41 |
| ▸ | GAK | O14976 | 1/20 | 0.41 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | STK17B | O94768 | 1/20 | 0.41 |
| ▸ | STK10 | O94804 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | FYN | P06241 | 1/20 | 0.41 |
| ▸ | FES | P07332 | 1/20 | 0.41 |
| ▸ | CSF1R | P07333 | 1/20 | 0.41 |
| ▸ | YES1 | P07947 | 1/20 | 0.41 |
| ▸ | LYN | P07948 | 1/20 | 0.41 |
| ▸ | MET | P08581 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19223200 | 0.95 | EGFR (0.47) | EGFRERBB2STK4STK25CIT | |
| SCHEMBL19223056 | 0.93 | EGFR (0.55) | EGFRERBB2STK4STK25CIT | |
| SCHEMBL19223117 | 0.90 | EGFR (0.47) | EGFRERBB2 | |
| SCHEMBL18949482 | 0.87 | EGFR (0.60) | EGFRERBB2STK4STK25CIT | |
| SCHEMBL19223025 | 0.86 | EGFR (0.47) | EGFRERBB2MAP2K1 | |
| SCHEMBL19223028 | 0.84 | EGFR (0.49) | EGFRERBB2 | |
| SCHEMBL18949427 | 0.81 | EGFR (0.58) | EGFRERBB2STK4STK25CIT | |
| SCHEMBL19223030 | 0.81 | EGFR (0.47) | EGFRERBB2 | |
| SCHEMBL18933435 | 0.80 | EGFR (0.50) | EGFRERBB2STK4STK25CIT | |
| SCHEMBL19223044 | 0.79 | EGFR (0.51) | EGFRERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10246443-B2 | Cyanoquinoline derivatives | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2019-04-02 | — | — | US | disclosed |
| US-20170226093-A1 | CYANOQUINOLINE DERIVATIVES | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2017-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10246443-B2 | Cyanoquinoline derivatives | CBR3, CYP3A4, CDK1 | EGFR 4737/4885ERBB2 3796/4885STK4 233/4885 |
| US-20170226093-A1 | CYANOQUINOLINE DERIVATIVES | CBR3, CYP3A4, CDK1 | EGFR 4737/4885ERBB2 3796/4885STK4 233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.